Professor Richard Scolyer, a world-renowned melanoma pathologist and former Australian of the Year, died on June 7, 2026 [2].
Scolyer was a leading figure in oncology whose work transformed melanoma treatment and pushed the boundaries of brain cancer research. His death marks the loss of a scientist who spent his final years testing the very treatments he helped design to save others.
Scolyer died at age 59 [1]. He died of glioblastoma, an aggressive form of brain tumor that was diagnosed in 2023 [3]. During his illness, he underwent a world-first experimental brain-tumor treatment that he helped develop [2].
Throughout his career, Scolyer earned international acclaim for his contributions to medicine. He was named Australian of the Year in 2024 [4]. His research focused heavily on melanoma, where he pioneered methodologies that improved patient outcomes globally [1].
In a final message, Scolyer said others should "pursue your dreams and passion with humility, love and compassion" [5]. He said he wanted to be remembered as a "proud everyday Aussie who gave it a crack" [6].
Scolyer's legacy is tied to his willingness to integrate his clinical research with his own patient experience. By participating in the experimental treatment he helped design, he provided critical data on the efficacy of new therapies for glioblastoma [2].
“Pursue your dreams and passion with humility, love and compassion.”
Scolyer's decision to undergo his own experimental treatment highlights a rare intersection of clinical research and personal patient advocacy. His work in melanoma and glioblastoma provides a foundation for future personalized cancer therapies, while his public battle with the disease brought global attention to the urgency of brain tumor research.
